Skip to content

Bicara Therapeutics BCAX Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Amgen logo
AmgenAMGN
$246.43B+9.9%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$958.05M+65.4%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's enterprise value?
Bicara Therapeutics (BCAX) reported enterprise value of $966.81M in Q1 2026.
How has Bicara Therapeutics's enterprise value changed year-over-year?
Bicara Therapeutics's enterprise value increased by 288.3% year-over-year, from $248.96M to $966.81M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.